维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="Bichev"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)显示文摘	Peter C. Thuss-Patience Albrecht Kretzschmar Dmitry Bichev Tillman Deist Axel Hinke Kirstin Breithaupt Yasemin Dogan Bernhard Gebauer Guido Schumacher Peter Reichardt	2011	European Journal of Cancer2011，，15：	5
2	Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)显示文摘	THUSS-PATIENCE PC KRETZSCHMAR A BICHEV D	2011	EurJCancer2011，47，15：	1
3	Survival advan-tage for irinotecan versus best supportive care as second-line chemo-therapy in gastric cancer--a randomised phase Ⅲstudy of the Arbeits-gemeinschaft Internistische Onkologie (AIO)显示文摘	Thuss-Patience PC Kretzschmar A Bichev D		0，，15：	1
4	Survivaladvantage for irinotecan versus best supportive care as second-linechemotherapy in gastric cancer--a randomised phase III study ofthe Arbeitsgemeinschaft Internistische Onkologie(AIO)显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur JCancer2011，47，15：	1
5	Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer:an analysis in Western patients显示文摘	Flrcken A Schaefer C Bichev D		0，，01：	1
6	Surviv-al advantage for irinotecan versus best supportive care as sec-ond-line chemotherapy in gastric cancer-a randomised phaseIII study of the Arbeitsgemeinschaft Internistische Onkologie(AI())显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
7	Implementation of qPCR and sequencing for KRAS and EGFR mutation detection in bul- garian patients with coloreetal and lung cancer 显示文摘	Bichev S Hristova S Slavova Y	2010	European Journal of Cancer Supplements2010，8，：	1
8	Survival advantage for irinotecan versus best supportive care as sec- ond-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) 显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
9	Survival advan tage for irinotecan versus best supportive care as second-line che motherapy in gastric cancer-a randomised Phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie(AIO显示文摘	Thuss-Patience P Kretzschmar A Bichev D		0，，15：	1
10	Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer- a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) 显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
11	An overview of location-based services显示文摘	Roza T D and Bichev G	2003	BT Technology Journal2003，21，1：	1
12	Survival advan- tage for irinotecan versus best supportive care as second-line che- motherapy in gastric cancer-a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) 显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Can- cer2011，47，15：	1
13	Survival ad- vantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie ( AIO ) 显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	European Journal of Cancer2011，47，15：	1
14	Sur-vival advantage for irinotecan versus best supportive careas second-line chemotherapy in gastric cancer-a ran-domised phase HI study of the Arbeitsgemeinschaft In-temistische Onkologie (AIO)显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
15	An overview of location-based services显示文摘	Roza T Bichev G	2003	BT Technology Journal2003，21，1：	1
16	-Survival advantage for irinoteean versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase ⅡI study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)显示文摘	Thuss-Patience PC Kretzsehmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
17	Survival advantage for irinoteean versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) 显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，15：	1
18	Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)显示文摘	Peter C. Thuss-Patience Albrecht Kretzschmar Dmitry Bichev Tillman Deist Axel Hinke Kirstin Breithaupt Yasemin Dogan Bernhard Gebauer Guido Schumacher Peter Reichardt	2011	European Journal of Cancer2011，，15：	1
19	Survial advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomized phase Ⅲ study of the Arbeitsgemeinschaft Internistische OnkoLogie(AIO)显示文摘	Thuss-Patience PC Kretzschmar A Bichev D		0，，15：	1
20	Survival advantage for irinotecan versus best supportive care sa second line chemotherapy in gastric cancer--a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)显示文摘	Thuss-Patience PC Kretzschmar A Bichev D	2011	Eur J Cancer2011，47，23：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示